Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma cell neoplasms (PCN) using next-generation flow cytometry (NGF) and correlated our findings with the distinct diagnostic and prognostic categories of the disease. Overall, 508 samples from 264 newly diagnosed PCN patients, were studied. CTPC were detected in PB of all active multiple myeloma (MM; 100%), and smoldering MM (SMM) patients (100%), and in more than half (59%) monoclonal gammopathy of undetermined significance (MGUS) cases (p
The reason why a few myeloma cells egress from the bone marrow (BM) into peripheral blood (PB) remai...
Multiple myeloma (MM) remains an incurable disease despite recent therapeutic improvements. The abil...
Background. Immunophenotyping by multiparameter flow cytometry (MFC) provides relevant information ...
Here, we investigated for the first time the frequency and number of circulating tumor plasma cells ...
This article belongs to the Special Issue Circulating Tumor Cells' Heterogeneity and Precision Oncol...
Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma ce...
The Oncology Grand Rounds series is designed to place original reports published in the Journal into...
Multiple myeloma (MM) patients undergo repetitive bone marrow (BM) aspirates for genetic characteriz...
International audienceBACKGROUND: Flow cytometry is the sole available technique for quantification ...
PURPOSE High levels of circulating tumor plasma cells (CTC-high) in patients with multiple myeloma a...
Plasma cell neoplasms comprise a spectrum of diseases that include monoclonal gammopathy of undeterm...
Background and aim: The clinical impact of multiparametric flow cytometry (MFC) in multiple myeloma ...
Smoldering multiple myeloma (SMM) carries a 50 % risk of progression to multiple myeloma (MM) or rel...
In multiple myeloma (MM), circulating tumor plasma cells (CTPCs) are an emerging prognostic factor, ...
[Purpose]: Patients with multiple myeloma (MM) may show patchy bone marrow (BM) infiltration and ext...
The reason why a few myeloma cells egress from the bone marrow (BM) into peripheral blood (PB) remai...
Multiple myeloma (MM) remains an incurable disease despite recent therapeutic improvements. The abil...
Background. Immunophenotyping by multiparameter flow cytometry (MFC) provides relevant information ...
Here, we investigated for the first time the frequency and number of circulating tumor plasma cells ...
This article belongs to the Special Issue Circulating Tumor Cells' Heterogeneity and Precision Oncol...
Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma ce...
The Oncology Grand Rounds series is designed to place original reports published in the Journal into...
Multiple myeloma (MM) patients undergo repetitive bone marrow (BM) aspirates for genetic characteriz...
International audienceBACKGROUND: Flow cytometry is the sole available technique for quantification ...
PURPOSE High levels of circulating tumor plasma cells (CTC-high) in patients with multiple myeloma a...
Plasma cell neoplasms comprise a spectrum of diseases that include monoclonal gammopathy of undeterm...
Background and aim: The clinical impact of multiparametric flow cytometry (MFC) in multiple myeloma ...
Smoldering multiple myeloma (SMM) carries a 50 % risk of progression to multiple myeloma (MM) or rel...
In multiple myeloma (MM), circulating tumor plasma cells (CTPCs) are an emerging prognostic factor, ...
[Purpose]: Patients with multiple myeloma (MM) may show patchy bone marrow (BM) infiltration and ext...
The reason why a few myeloma cells egress from the bone marrow (BM) into peripheral blood (PB) remai...
Multiple myeloma (MM) remains an incurable disease despite recent therapeutic improvements. The abil...
Background. Immunophenotyping by multiparameter flow cytometry (MFC) provides relevant information ...